File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Comprehensive analyses of m6A regulators and interactive coding and non-coding RNAs across 32 cancer types

TitleComprehensive analyses of m6A regulators and interactive coding and non-coding RNAs across 32 cancer types
Authors
KeywordsN6-Methyladenosine
Pan-cancer
Survival outcome
Multi-omics
Issue Date2021
PublisherBioMed Central Ltd. The Journal's web site is located at http://www.molecular-cancer.com
Citation
Molecular Cancer, 2021, v. 20, article no. 67 How to Cite?
AbstractN6-Methyladenosine (m6A) is an RNA modification that interacts with numerous coding and non-coding RNAs and plays important roles in the development of cancers. Nonetheless, the clinical impacts of m6A interactive genes on these cancers largely remain unclear since most studies focus only on a single cancer type. We comprehensively evaluated m6A modification patterns, including 23 m6A regulators and 83 interactive coding and non-coding RNAs among 9,804 pan-cancer samples. We used clustering analysis to identify m6A subtypes and constructed the m6A signature based on an unsupervised approach. We used the signatures to identify potential m6A modification targets across the genome. The prognostic value of one target was further validated in 3,444 samples from six external datasets. We developed three distinct m6A modification subtypes with different tumor microenvironment cell infiltration degrees: immunological, intermediate, and tumor proliferative. They were significantly associated with overall survival in 24 of 27 cancer types. Our constructed individual-level m6A signature was associated with survival, tumor mutation burden, and classical pathways. With the signature, we identified 114 novel genes as potential m6A targets. The gene shared most commonly between cancer types, BCL9L, is an oncogene and interacts with m6A patterns in the Wnt signaling pathway. In conclusion, m6A regulators and their interactive genes impact the outcome of various cancers. Evaluating the m6A subtype and the signature of individual tumors may inform the design of adjuvant treatments.
Persistent Identifierhttp://hdl.handle.net/10722/306308
ISSN
2023 Impact Factor: 27.7
2023 SCImago Journal Rankings: 8.222
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorShen, S-
dc.contributor.authorZhang, R-
dc.contributor.authorJiang, Y-
dc.contributor.authorLi, Y-
dc.contributor.authorLin, L-
dc.contributor.authorLiu, Z-
dc.contributor.authorZhao, Y-
dc.contributor.authorShen, H-
dc.contributor.authorHu, Z-
dc.contributor.authorWei, Y-
dc.contributor.authorChen, F-
dc.date.accessioned2021-10-20T10:21:46Z-
dc.date.available2021-10-20T10:21:46Z-
dc.date.issued2021-
dc.identifier.citationMolecular Cancer, 2021, v. 20, article no. 67-
dc.identifier.issn1476-4598-
dc.identifier.urihttp://hdl.handle.net/10722/306308-
dc.description.abstractN6-Methyladenosine (m6A) is an RNA modification that interacts with numerous coding and non-coding RNAs and plays important roles in the development of cancers. Nonetheless, the clinical impacts of m6A interactive genes on these cancers largely remain unclear since most studies focus only on a single cancer type. We comprehensively evaluated m6A modification patterns, including 23 m6A regulators and 83 interactive coding and non-coding RNAs among 9,804 pan-cancer samples. We used clustering analysis to identify m6A subtypes and constructed the m6A signature based on an unsupervised approach. We used the signatures to identify potential m6A modification targets across the genome. The prognostic value of one target was further validated in 3,444 samples from six external datasets. We developed three distinct m6A modification subtypes with different tumor microenvironment cell infiltration degrees: immunological, intermediate, and tumor proliferative. They were significantly associated with overall survival in 24 of 27 cancer types. Our constructed individual-level m6A signature was associated with survival, tumor mutation burden, and classical pathways. With the signature, we identified 114 novel genes as potential m6A targets. The gene shared most commonly between cancer types, BCL9L, is an oncogene and interacts with m6A patterns in the Wnt signaling pathway. In conclusion, m6A regulators and their interactive genes impact the outcome of various cancers. Evaluating the m6A subtype and the signature of individual tumors may inform the design of adjuvant treatments.-
dc.languageeng-
dc.publisherBioMed Central Ltd. The Journal's web site is located at http://www.molecular-cancer.com-
dc.relation.ispartofMolecular Cancer-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectN6-Methyladenosine-
dc.subjectPan-cancer-
dc.subjectSurvival outcome-
dc.subjectMulti-omics-
dc.titleComprehensive analyses of m6A regulators and interactive coding and non-coding RNAs across 32 cancer types-
dc.typeArticle-
dc.identifier.emailLiu, Z: zhhliu@hku.hk-
dc.identifier.authorityLiu, Z=rp02429-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1186/s12943-021-01362-2-
dc.identifier.pmid33849552-
dc.identifier.pmcidPMC8045265-
dc.identifier.scopuseid_2-s2.0-85104317064-
dc.identifier.hkuros327200-
dc.identifier.volume20-
dc.identifier.spagearticle no. 67-
dc.identifier.epagearticle no. 67-
dc.identifier.isiWOS:000639839000001-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats